Stockscreener 앱 받기
13.62
0.15%
0.02
시장 영업 전:
13.62
전일 마감가:
$13.60
열려 있는:
$13.56
하루 거래량:
1.46M
Relative Volume:
0.22
시가총액:
$3.58B
수익:
$6.16B
순이익/손실:
$246.00M
주가수익비율:
14.51
EPS:
0.9387
순현금흐름:
$708.00M
1주 성능:
+0.44%
1개월 성능:
+0.74%
6개월 성능:
+74.39%
1년 성능:
+47.72%
1일 변동 폭
$13.56
$13.63
1주일 범위
$13.54
$13.63
52주 변동 폭
$5.69
$13.63
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.62 | 3.56B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,231.94 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.81 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
247.97 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.92 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.79 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
OGN|Organon & Co|Price:13.535|Chg%:+0.015 - TradingKey
India healthcare M&A hits record value as pharma takes centre stage - DealStreetAsia
OGN Looks 6.8% Undervalued on GF Value™ - GuruFocus
Organon & Co (OGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organon & Co. (OGN) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
OGN|Organon & Co|Price:13.520| - TradingKey
Organon & Co (OGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organon & Co (OGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Organon & Co. (OGN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
India’s pharma M&A market hits four-year high on blockbuster deals - The Pharma Letter
Sun Pharma Clears Key Milestone as Organon Shareholders Back USD 11.75 Billion Buyout - Medical Dialogues
Sun Pharma Receives Organon Shareholder Approval for Proposed Acquisition - Machine Maker
Organon & Co. (OGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon shareholders approve Sun Pharma acquisition proposal - Indian Pharma Post
Organon & Co. (OGN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 - Lelezard
Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8 - Stock Titan
Sun Pharma gets Organon shareholders’ nod for its $11.75-bn acquisition proposal - BusinessLine
Organon & Co. (OGN) 8-K Filing: Key Stockholder Vote Results and Company Information – July 2026 - Minichart
Organon shareholders approve merger with Sun Pharma - Fortune India
Organon Shareholders Approve Sun Pharma Merger, Deal Nears Completion - outlookbusiness.com
Sun Pharma Stock Slips as Organon Holders Approve Merger - Equitypandit
Organon shareholders approve Sun Pharma's $11.75-bn acquisition proposal - The Economic Times
Organon Shareholders Approve Sun Pharma’s USD 11.75-bn Acquisition Proposal - HDFC Sky
Sun Pharma Moves Closer To Record $12 Billion Organon Deal After Shareholders Approval - NDTV Profit
OGN|Organon & Co|Price:13.520|Chg%:-0.035 - TradingKey
Sun Pharma inches closer to biggest-ever buyout as Organon shareholders approve merger - Moneycontrol.com
Sun Pharma receives Organon shareholders approval for merger - Business Standard
Sun Pharma moves closer to Organon acquisition as shareholders approve deal; stock in focus - Upstox
Organon Shareholders Endorse Merger with Sun Pharmaceutical Holdings USA in July 2026 Vote - Kalkine Media
Organon & Co. Shareholders Clear Sun Pharma Merger Deal - TradingView
Organon holds special shareholder meeting on merger agreement proposal - Bitget
Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality - simplywall.st
Organon (OGN) Proxy filing Summary - Quartr
ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR - marketscreener.com
Press Release: ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR - Moomoo
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Price-Driven Insight from (OGN) for Rule-Based Strategy - Stock Traders Daily
Organon stock trades steady as women’s health focus meets mixed earnings momentum - Ad-hoc-news.de
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오가논 & Co 주식 (OGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Head of Mfg & Supply |
Aug 05 '26 |
Sale |
13.57 |
14,761 |
200,307 |
18,475 |
1.08%
0.11%
자본화:
|
볼륨(24시간):